Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence

Neuropharmacology

Volumn 43, Issue 5, 2002, Pages 857-867

  Castane A ^a   Valjent, E ^a   Ledent, C ^b   Parmentier, M ^b   Maldonado, R ^a   Valverde, O ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cannabinoid; CB1 cannabinoid receptor; Conditioning place preference; Mice; Nicotine; Nociception; Withdrawal

Indexed keywords

CANNABINOID 1 RECEPTOR; MECAMYLAMINE; NICOTINE TARTRATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; HOT PLATE TEST; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTIVATION; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; TASK PERFORMANCE; WILD TYPE; WITHDRAWAL SYNDROME;

EID: 0036800871     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00118-1     Document Type: Article

References (57)

1. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 91:1996;1585-1614.
2. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
3. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology. 153:2000;31-43.
4. Clarke P.B.S., Kumar R. The effects of nicotine on locomotor activity in non-tolerant rats and tolerant rats. British Joutnal of Pharmacology. 78:1983;329-337.
5. Cossu G., Ledent C., Fattore L., Imperato A., Bohme G.A., Parmentier M., Fratta W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural Brain Research. 118:2001;61-65.
6. Degenhardt L., Hall W., Lynskey M. Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction. 96:2001;1603-1614.
7. Dewey W.L. Cannabinoid pharmacology. Pharmacological Reviews. 38:1986;151-178.
8. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Science USA. 85:1988;5274-5278.
9. Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature. 393:1998;76-79.
10. Fattore L., Martellotta M.C., Cossu G., Mascia M.S., Fratta W. CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behavioural Brain Research. 104:1999;141-146.
11. Gardner E.L., Paredes W., Smith D., Donner A., Milling C., Cohen D., Morrison D. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology. 96:1988;142-144.
12. Grossman M.L., Basbaum A.I., Fields H.L. Afferent and efferent connections of the rat tail flick reflex (a model used to analyze pain control mechanisms). Journal of Comparative Neurology. 206:1982;9-16.
13. Hernandez-Tristan R., Arevalo C., Canals S., Leret M.L. The effects of acute treatment with delta9-THC on exploratory behaviour and memory in the rat. Journal of Physiology and Biochemistry. 56:2000;17-24.
14. Hildebrand B.E., Nomikos G.G., Bondjers C., Nisell M., Svensson T.H. Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology. 129:1997;348-356.
15. Hildebrand B.E., Nomikos G.G., Hertel P., Schilstrom B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Research. 779:1998;214-225.
16. Hildebrand B.E., Panagis G., Svensson T.H., Nomikos G.G. Behavioural and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology. 21:1999;560-574.
17. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., Fenwick J.W. Symptoms of tobacco withdrawal. A replication and extension. Archives of General Psychiatry. 48:1991;52-59.
18. Isola R., Vogelsberg V., Wemlinger T.A., Neff N.H., Hadjiconstantinou M. Nicotine abstinence in the mouse. Brain Research. 850:1999;189-196.
19. Jones B.C., Consroe P.F., Laird 2nd H.E. The interaction of delta9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm. European Journal of Pharmacology. 38:1976;253-259.
20. Khan I.M., Yaksh T.L., Taylor P. Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: studies with nicotine and cytisine. Journal of Pharmacology and Experimental Therapeutics. 270:1994;159-166.
21. Koob G.F., Nestler E.J. The neurobiology of drug addiction. Journal of Neuropsychiatry and Clinical Neurosciences. 9:1997;482-497.
22. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283:1999;401-404.
23. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. Journal of Pharmacology and Experimental Therapeutics. 258:1991;517-523.
24. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
25. Maldonado R., Saiardi A., Valverde O., Samad T.A., Roques B.P., Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature. 388:1997;586-589.
26. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. European Journal of Neuroscience. 12:2000;4038-4046.
27. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology. 159:2002;379-387.
28. Martin W.J., Lai N.K., Patrick S.L., Tsou K., Walker J.M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Research. 629:1993;300-304.
29. Martin W.J., Patrick S.L., Coffin P.O., Tsou K., Walker J.M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sciences. 56:1995;2103-2109.
30. Marubio L.M., del Mar Arroyo-Jimenez M., Cordero-Erausquin M., Lena C., Le Novère N., de Kerchove d'Exaerde A., Huchet M., Damaj M.I., Changeux J.P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature. 398:1999;805-810.
31. Mascia M.S., Obinu M.C., Ledent C., Parmentier M., Bohme G.A., Imperato A., Fratta W. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. European Journal of Pharmacology. 383:1999;R1-R2.
32. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 383:1996;819-823.
33. Morgan M.M., Sohn J.H., Liebeskind J.C. Stimulation of the periaqueductal gray matter inhibits nociception at the supraspinal as well as spinal level. Brain Research. 502:1989;61-66.
34. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., de Fonseca F.R. Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience. 21:2001;5344-5350.
35. Picciotto M.R., Zoli M., Léna C., Bessis A., Lallemand Y., Le Novère N., Vincent P., Pich E.M., Brulet P., Changeux J.P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature. 374:1995;65-67.
36. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., Fuxe K., Changeux J.P. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 391:1998;173-177.
37. Picciotto M.R., Caldarone B.J., King S.L., Zachariou V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology. 22:2000;451-465.
38. Pontieri F.E., Tanda G., Orzi F., Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 382:1996;255-257.
39. Pryor G.T., Larsen F.F., Husain S., Braude M.C. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacology Biochemistry and Behaviour. 8:1978;295-318.
40. Puttfarcken P.S., Manelli A.M., Arneric S.P., Donnelly-Roberts D.L. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells. Journal of Neurochemistry. 69:1997;930-938.
41. Quik M., Polonskaya Y., Gillespie A., Jakowec M., Lloyd G.K., Langston J.W. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. Journal of Comparative Neurology. 425:2000;58-69.
42. Risinger F.O., Oakes R.A. Nicotine-induced conditioned place preference and conditioned place aversion in mice. Pharmacology Biochemistry and Behaviour. 51:1995;457-461.
43. Sañudo-Peña M.C., Strangman N.M., Mackie K., Walker J.M., Tsou K. CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Acta Pharmacological Sinica. 20:1999;1115-1120.
44. Schorling J.B., Gutgesell M., Klas P., Smith D., Keller A. Tobacco, alcohol and other drug use among college students. Journal of Substance Abuse. 6:1994;105-115.
45. Simonin F., Valverde O., Smadja C., Slowe S., Kitchen I., Dierich A., Le Meur M., Roques B.P., Maldonado R., Kieffer B.L. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO Journal. 17:1998;886-897.
46. Szabo B., Muller T., Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. Journal of Neurochemistry. 73:1999;1084-1089.
47. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
48. Valjent E., Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology. 147:2000;436-438.
49. Valjent E., Mitchell J.M., Besson M., Caboche J., Maldonado R. Behavioural and biochemical evidence for interactions between Δ9-tetrahydrocannabinol and nicotine. British Journal of Pharmacology. 135:2002;564-578.
50. Valverde O., Fournie-Zaluski M.C., Roques B.P., Maldonado R. The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacology. 123:1996;119-126.
51. Valverde O., Ledent C., Beslot F., Parmentier M., Roques B.P. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. European Journal of Neuroscience. 12:2000;533-539.
52. Walker J.M., Hohmann A.G., Martin W.J., Strangman N.M., Huang S.M., Tsou K. The neurobiology of cannabinoid analgesia. Life Sciences. 65:1999;665-673.
53. Watkins S.S., Epping-Jordan M.P., Koob G.F., Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacology Biochemistry and Behaviour. 62:(743-75):1999;1.
54. Watkins S.S., Koob G.F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tobacco Research. 2:2000;19-37.
55. Watson S.J., Benson Jr J.A., Joy J.E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Archives of General Psychiatry. 57:2000;547-552.
56. West R.J., Hajek P., Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychological Medicine. 19:1989;981-985.
57. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Science USA. 96:1999;5780-5785.